Generic medicines and generic substitution: Contrasting perspectives of stakeholders in Ireland

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  O'Leary, A ^a,b   Usher, C ^a   Lynch, M ^b   Hall, M ^a   Hemeryk, L ^a   Spillane, S ^a   Gallagher, P ^b   Barry, M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Generic medicines; Generic substitution; Key stakeholders; Knowledge; Perception

Indexed keywords

GENERIC DRUG;

ATTITUDE TO HEALTH; DRUG SUBSTITUTION; FEMALE; GENERAL PRACTITIONER; HEALTH PERSONNEL ATTITUDE; HUMAN; IRELAND; MALE; PATIENT; PHARMACIST; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ATTITUDE OF HEALTH PERSONNEL; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; GENERAL PRACTITIONERS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IRELAND; MALE; PATIENTS; PHARMACISTS; SURVEYS AND QUESTIONNAIRES;

EID: 84987651013     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1764-x     Document Type: Article

References (50)

1. Cameron A, Ewen M, Auton M, Abegunde D. The World Medicines Situation 3rd edition: Medicines prices, availability and affordability. [Internet]. Geneva: World Health Organisation; 2011. http://www.who.int/medicines/areas/policy/world-medicines-situation/WMS-ch6-wPricing-v6.pdf.
2. World Health Organisation. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research [Internet]. 2015. http://www.euro.who.int/--data/assets/pdf-file/0003/273819/WHO-Medicines-Report-FINAL2015.pdf?ua=1.
3. Statistical Analysis of Claims and Payments 2013. [Internet]. Health Service Executive Primary Care Reimbursement Service; [cited 2015 Oct 20]. http://www.hse.ie/eng/staff/PCRS/PCRS-Publications/PCRS-Statistical-Analyis-of-Claims-and-Payments-2013.pdf.
4. Barry M, Molloy D, Usher C, Tilson L. Drug expenditure in Ireland 1997-2007. Ir Med J. 2008;101(10):299-302.
5. OECD. Health at a Glance: Europe 2012 [Internet]. OECD Publishing; 2012 [cited 2015 Oct 20]. OECD Publishing. http://dx.doi.org/10.1787/9789264183896-en.
6. Gorecki P, Nolan A, Brick A, Lyons S. Delivery of Pharmaceuticals in Ireland: Getting a Bigger Bang for the Buck. [Internet]. The Economic and Social Research Institute; 2012 Jan. Report No.: 24. https://www.esri.ie/pubs/RS24.pdf.
7. Ex post Evaluation of the Economic Adjustment Programme: Ireland, 2010-2013. [Internet]. Luxembourg: European Commission; 2015. Report No.: 004. http://ec.europa.eu/economy-finance/publications/eeip/pdf/ip004-en.pdf.
8. Brick A, Gorecki P, Nolan A. Pharmaceutical Prices, Prescribing Practices and Usage of Generics. [Internet]. The Economic and Social Research Institute; 2013 Jun. Report No.: 32. https://www.esri.ie/pubs/RS32.pdf.
9. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):59-72.
10. McGettigan P, McManus J, O'Shea B, Chan R, Feely J. Low rate of generic prescribing in the Republic of Ireland compared to Eng land and Northern Ireland: prescribers' concerns. Ir Med J. 1997;90:146-7.
11. Usher C, Tilson L, Bennett K, Barry M. Cost containment interventions introduced on the community drugs schemes in Ireland - evaluation of expenditure trends using a national prescription claims database. Clin Ther. 2012;34(3):632-9.
12. Barry M. Economies in drug usage in the Irish Healthcare Setting. 2008. http://www.dohc.ie/publications/pdf/economies-drug-usage.pdf?direct=1.
13. Health Act 2013. http://www.irishstatutebook.ie/2013/en/act/pub/0014/sec0001.html#sec1.
14. Himmel W, Simmenroth-Nayda A, Nieblung W. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther. 2005;43:472-9.
15. Heikkila R, Mantyselka P, Hartikainen-Herranen K, Ahonen R. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82:366-74.
16. Chong C, Hassali M, Bahari M, Shafie A. Generic medicine substitution practices among community pharmacists: a nationwide study from Malaysia. J Public Health. 2011;19(1):81-90.
17. Olsson E, Kälvemark Sporrong S. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012;20(6):377-83.
18. Keenum AJ, Devoe JE, Chisolm DJ, Wallace LS. Generic medications for you, but brand-name medications for me. Res Social Adm Pharm. 2012;8(6):574-8.
19. Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract. 2014;31(4):467-74.
20. Dunne S, Shannon B, Dunne C, Cullen W. Patient perceptions of generic medicines: a mixed-methods study. Patient Patient Orient Outcomes Res. 2014;7(2):177-85.
21. Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341-8.
22. Kjoenniksen I, Lindbaek M, Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28:284-9.
23. Heikkilä R, Mäntyselkä P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. BMC Clin Pharmacol. 2010;22:10-5.
24. Hassali MA, Shafie AA, Jamshed S, Ibrahim MI, Awaisu A. Consumers' views on generic medicines: a review of the literature. Int J Pharm Pract. 2009;17(2):79-88.
25. Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists. Pharm World Sci. 2003;25(5):197-202.
26. Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy. 2012;104(1):61-8.
27. Mott DA, Cline RR. Exploring generic drug use behaviour: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40(8):662-74.
28. Heikkilä R, Mäntyselkä P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20(2):185-91.
29. Krska J, Allison K, Delargy M, Murray L, Smith H. Implementing a statin switching programme in primary care: patients' views and experiences. Br J Clin Pharmacol. 2012;74(1):147-53.
30. Håkonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr Med Res Opin. 2009;25(10):2515-21.
31. Nunes V, Neilson J, O'Flynn N, Calvert N, Kuntze S, Smithson H, Benson J, Blair J, Bowser A, Clyne W, Crome P, Haddad P, Hemingway S, Horne R, Johnson S, Kelly S, Packham B, Patel M, Steel J. Clinical Guidelines and Evidence Review for Medicines Adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2009.
32. Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, Choudhry NK. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013;173(3):202-8.
33. Avery AJ, Rodgers S, Heron T, Crombie R, Whynes D, Pringle M, Baines D, Petchey R. A prescription for improvement? An observational study to identify how general practices vary in their growth in prescribing costs. BMJ. 2000;321(7256):276-81.
34. Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W. Physician and pharmacist perceptions of generic medicines: What they think and how they differ. Health Policy. 2014;116(2):214-23.
35. Chambers JA, O'Carroll RE, Dennis M, Sudlow C, Johnston M. "My doctor has changed my pills without telling me": impact of generic medication switches in stroke survivors. J Behav Med. 2013;37(5):890-901.
36. Toverud EL, Røise AK, Hogstad G, Wabø I. Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences. Eur J Clin Pharmacol. 2011;67(1):33-8.
37. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother. 2006;40(1):15-20.
38. Olesen C, Harbig P, Barat I, Damsgaard EM. Generic substitution does not seem to affect adherence negatively in elderly polypharmacy patients. Pharmacoepidemiol Drug Saf. 2013;22(10):1093-8.
39. Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health (Oxf). 2005;27(3):281-91.
40. World Health Organisation. The World Health Report 2010: health systems financing: the path to universal coverage. Geneva 2010. http://www.who.int/whr/2010/whr10-en.pdf?ua=1.
41. Meredith PA. Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin. 2009;25(9):2179-89.
42. Sander JW, Ryvlin P, Stefan H, Booth DR, Bauer J. Generic substitution of antiepileptic drugs. Expert Rev Neurother. 2010;10(12):1887-98.
43. Yamada M, Welty TE. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother. 2011;45(11):1406-15.
44. Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, Witt DM, Ageno W, Warfarin Associated Research Projects and Other Endeavors (WARPED) Consortium. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011;31(4):386-93.
45. Krauss GL, Caffo B, Chang YT, Hendrix CW, Chuang K. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol. 2011;70(2):221-8.
46. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142(11):891-7.
47. Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010;70(3):320-34.
48. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1.
49. Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med. 2012;367(18):1679-81.
50. Kesselheim AS, Green MD, Avorn J. Who is now responsible for discovering and warning about adverse effects of generic drugs? JAMA. 2013;310(10):1023-4.